|
Aug 12
|
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 12
|
Durect: Q2 Earnings Snapshot
|
|
Aug 12
|
DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health
|
|
Aug 9
|
Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment
|
|
Jul 30
|
Bausch Health Announces Second Quarter 2025 Results
|
|
Jul 30
|
3 Promising Penny Stocks With Market Caps Over $10M
|
|
Jul 29
|
Bausch Health to Acquire Nasdaq-listed Durect for US$63 Million
|
|
Jul 29
|
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
|
|
Jan 16
|
Durect (DRRX) Upgraded to Strong Buy: Here's Why
|
|
Oct 9
|
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ...
|
|
Sep 25
|
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
|
|
Jun 19
|
Are Medical Stocks Lagging DURECT (DRRX) This Year?
|
|
May 21
|
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
|
|
May 14
|
Q1 2024 DURECT Corp Earnings Call
|
|
May 14
|
Durect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...
|
|
May 13
|
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 13
|
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
|
|
May 7
|
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
|
|
Apr 30
|
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
|
|
Apr 1
|
DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript
|